Search results for "Papillomavirus Infections"

showing 10 items of 113 documents

2018

Oncogenic human papillomaviruses (HPV) are small DNA viruses that infect keratinocytes. After HPV binding to cell surface receptors, a cascade of molecular interactions mediates the infectious cellular internalization of virus particles. Aside from the virus itself, important molecular players involved in virus entry include the tetraspanin CD151 and the epidermal growth factor receptor (EGFR). To date, it is unknown how these components are coordinated in space and time. Here, we studied plasma membrane dynamics of CD151 and EGFR and the HPV16 capsid during the early phase of infection. We find that the proteinase ADAM17 activates the extracellular signal-regulated kinases (ERK1/2) pathway…

Keratinocytes0301 basic medicineCarcinogenesisvirusesEndocytic cycle610 MedizinTetraspanin610 Medical sciencesEpidermal growth factor receptorBiology (General)InternalizationPapillomaviridaemedia_commonHuman papillomavirus 16Microbiology and Infectious DiseaseADAM17General NeuroscienceQRoncogenic PapillomavirusGeneral MedicineEndocytosisCell biologyErbB ReceptorsCapsidMedicinemicrodomainsResearch ArticleHumanQH301-705.5MAP Kinase Signaling SystemSciencemedia_common.quotation_subject030106 microbiologyADAM17 ProteinTetraspanin 24BiologyGeneral Biochemistry Genetics and Molecular BiologyVirus03 medical and health sciencesCell surface receptorViral entrygrowth factorsHumansGeneral Immunology and MicrobiologyCell MembranePapillomavirus InfectionsVirionentry receptor complexCell BiologyVirus Internalizationtetraspanin030104 developmental biologybiology.proteinHeLa CellseLife
researchProduct

Chapter 14: HPV vaccine introduction in industrialized countries.

2006

Introduction of a vaccine requires the achievement of three initial milestones. These are licensure by a national control authority that determines the vaccine is safe and effective, development of recommendations for use by expert advisory bodies on immunization, and obtaining funding for vaccination. Once these milestones have been achieved, a successful vaccination program requires that a number of interlinked programmatic components be brought together in a coordinated fashion. These include vaccine purchase and supply, vaccination service delivery, high coverage rates, surveillance of the vaccination program, immunization finance policies and practices, and political will. Human papill…

LicensureEconomic growthGeneral VeterinaryGeneral Immunology and MicrobiologyService delivery frameworkbusiness.industryDeveloped CountriesPapillomavirus InfectionsPublic Health Environmental and Occupational HealthImmunization (finance)High coverageVaccine introductionVaccinationInfectious DiseasesImmunologyMolecular MedicineMedicineHumansFemalePapillomavirus VaccinesHuman papillomavirusbusinessDeveloped countryHealth Services AdministrationVaccine
researchProduct

Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.

2010

The effect of combining sodium butyrate (NaB), a histone deacetylase inhibitor, and 7-hydroxy-staurosporine (UCN-01) on cytotoxicity in human cervical carcinoma cells was evaluated.HeLa and CaSki cells were treated using NaB alone or in combination with staurosporine (STS) or its analog UCN-01. Cytotoxicity was determined by flow cytometry and morphological assays. Apoptotic pathways were characterized by Western blotting and immunostaining. CaSki cells were also xenografted into nude mice to assess the in vivo effects of NaB/UCN-01 combination.Treatment with NaB and STS or UCN-01 resulted in enhanced apoptosis of cancer cells. Apoptosis involved mitochondrial pathways and overexpression of…

MESH : StaurosporineMESH : Hela CellsMESH : Antineoplastic Combined Chemotherapy Protocolshealth care facilities manpower and servicesUterine Cervical NeoplasmsMESH: ButyratesMESH: Cell CycleApoptosisMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/CancerMiceAntineoplastic Combined Chemotherapy ProtocolsMESH: AnimalsMESH: Human papillomavirus 18MESH : Human papillomavirus 18MESH : Femalehealth care economics and organizationsMESH: Human papillomavirus 16MESH : Papillomavirus InfectionsHuman papillomavirus 16Human papillomavirus 18Cell CycleMESH : Mice NudeMESH: Uterine Cervical NeoplasmsMESH: Antineoplastic Combined Chemotherapy ProtocolsButyratesMESH: Cell Growth ProcessesFemaleMESH: Xenograft Model Antitumor Assaysendocrine systemMESH: Cell Line TumoreducationMESH : Uterine Cervical NeoplasmsMice Nude[SDV.CAN]Life Sciences [q-bio]/CancerCell Growth ProcessesMESH : Xenograft Model Antitumor Assays[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumorMESH : ButyratesMESH : MiceMESH : Cell CycleMESH: Mice Nudeotorhinolaryngologic diseasesAnimalsHumansMESH: MiceMESH: HumansMESH : Cell Line TumorMESH: ApoptosisPapillomavirus InfectionsMESH : HumansMESH : Human papillomavirus 16StaurosporineXenograft Model Antitumor AssaysMESH: Hela CellsMESH : Cell Growth ProcessesMESH: StaurosporineMESH : AnimalsMESH: FemaleMESH : ApoptosisHeLa Cells
researchProduct

[Vaccination against papillomavirus : arguments and evidence of effectiveness].

2020

Vaccination against papillomavirus: arguments and evidence of effectiveness. Vaccination against human papillomavirus is a major advance in the prevention of cervical cancer. Evidence of its effectiveness has accumulated over the past thirty years since basic research has demonstrated the ability of viral pseudoparticles to induce immune responses in animals. Large human clinical trials followed to demonstrate the safety and efficacy of vaccination against targeted HPV infections and their associated lesions. After its approval and marketing the vaccine efficacy was measured at the level of entire populations, confirming its effectiveness and medical interest. Today, models predict a possib…

MESH: HumansPapillomavirus InfectionsVaccinationUterine Cervical Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Papillomavirus VaccinesMESH: VaccinationMESH: Papillomavirus InfectionsMESH: Uterine Cervical Neoplasms[SDV.CAN] Life Sciences [q-bio]/CancerHumansFemalePapillomavirus VaccinesDisease EradicationMESH: FemaleLa Revue du praticien
researchProduct

Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC

2020

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negat…

MaleAPOBECCancer ResearchT-Lymphocytesmedicine.medical_treatment610BiologyCohort Studies03 medical and health sciences0302 clinical medicineGene expressionBiomarkers TumormedicineHumansExomeAPOBEC Deaminasestumor inflammationPapillomaviridaeExomeGeneImmune EvasionInflammationSequence Analysis RNASquamous Cell Carcinoma of Head and NeckPapillomavirus InfectionsAPOBECmutational signatureImmunotherapyMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaPhenotypeImmune checkpointddc:Gene Expression Regulation Neoplasticstomatognathic diseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisMutationCancer researchimmune checkpoint inhibitionFemalehead and neck cancerTranscriptome600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitInternational Journal of Cancer
researchProduct

USE OF FUZZY NEURAL NETWORKS IN MODELING RELATIONSHIPS OF HPV INFECTION WITH APOPTOTIC AND PROLIFERATION MARKERS IN POTENTIALLY MALIGNANT ORAL LESIONS

2005

To evaluate in oral leukoplakia the relationship between HPV infection and markers of apoptosis (bcl-2, survivin) and proliferation (PCNA), also conditionally to age, gender, smoking and drinking habits of patients, by means of Fuzzy neural networks (FNN) system 21 cases of oral leukopakia, clinically and histologically diagnosed, were examined for HPV DNA presence, bcl-2, survivin and PCNA expression. HPV DNA was investigated in exfoliated oral mucosa cells by nested PCR (nPCR: MY09-MY11/GP5-GP6), and the HPV genotype determined by direct DNA sequencing. All markers were investigated by means of standardised immunohistochemistry procedure. Data were analysed by chi-square test, crude OR an…

MaleCancer ResearchOral precancerous lesionSurvivinFuzzy neural networksApoptosisPolymerase Chain ReactionInhibitor of Apoptosis Proteinslaw.inventionlawGenotypePapillomaviridaePolymerase chain reactionLeukoplakiabiologySmokingHPV infectionvirus diseasesMiddle Agedfemale genital diseases and pregnancy complicationsNeoplasm ProteinsCell Transformation NeoplasticProto-Oncogene Proteins c-bcl-2OncologyCarcinoma Squamous CellFemaleMouth NeoplasmsLeukoplakia OralOral SurgeryMicrotubule-Associated ProteinsAdultHPVFuzzy LogicProliferating Cell Nuclear AntigenSurvivinCarcinomamedicineHumansBcl-2AgedCell ProliferationAnalysis of VariancePapillomavirus InfectionsMouth Mucosamedicine.diseaseProliferating cell nuclear antigenDNA ViralImmunologybiology.proteinCancer researchNeural Networks ComputerNested polymerase chain reaction
researchProduct

H3 and H3.3 histone mRNA amounts and ratio in oral squamous cell carcinoma and leukoplakia.

2006

Histone variants (e.g. H3) play an important role in chromatin structure and gene expression regulation of normal cells. Aims of this study were to: (1) estimate H3 and H3.3 histone mRNA expressions and their ratio in oral squamous cell carcinoma (OSCC) and oral leukoplakia (OL); (2) investigate whether H3 and H3.3 variants could play a role in the pathogenesis of OSCC and OL, also conditionally to HPV infection, age, gender, and main habits (tobacco smoking and alcohol drinking) in human beings studied. Twenty-three cases of OSCC and 20 cases of OL were examined in lesion site (LS) and juxtaposed clinically undamaged site (JUS) by RT-PCR for H3 and H3.3 histone mRNA; 13 healthy oral mucosa…

MaleHPVH3.3 histone mRNAAlcohol Drinking"carcinoma"BiologyH3 histone mRNAoral leukoplakiaPathogenesisHistonesleucoplakia"Sex FactorsRisk FactorsmedicineCarcinomaHumansRNA MessengerOral mucosaGeneral DentistryPapillomaviridaeLeukoplakiaAgedRegulation of gene expressionMessenger RNAPapillomavirus InfectionsSmoking"H3 histones"HPV infectionAge FactorsMouth MucosaMiddle Agedmedicine.diseaseMolecular biologyoral squamous cell carcinomastomatognathic diseasesmedicine.anatomical_structureHistoneOtorhinolaryngologyDNA Viralbiology.proteinCarcinoma Squamous CellFemaleMouth NeoplasmsLeukoplakia OralOral diseases
researchProduct

Overview of the benefitsand potential issues of the nonavalent HPV vaccine

2017

HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHP…

MaleHPVmedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseAnatomic region03 medical and health sciences0302 clinical medicineHPV nonavalent vaccinePrimary preventionEnvironmental healthmedicineHumansPapillomavirus Vaccines030212 general & internal medicineCervical cancer; HPV; HPV nonavalent vaccine; Prevention; Female; Humans; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Randomized Controlled Trials as Topic; Uterine Cervical NeoplasmsPapillomaviridaeRandomized Controlled Trials as TopicGynecologyCervical cancerbusiness.industryPreventionPapillomavirus InfectionsObstetrics and GynecologyHpv vaccinationGeneral Medicinemedicine.disease030220 oncology & carcinogenesisCervical cancer; HPV; HPV nonavalent vaccine; PreventionCervical cancerFemalebusiness
researchProduct

Human papilloma virus infection and vaccination: Pre-post intervention analysis on knowledge, attitudes and willingness to vaccinate among preadolesc…

2020

In recent years, vaccination coverage rates against Human Papilloma Virus (HPV) in Europe have shown a decreasing trend and remain below the required standard. The present study aims to assess knowledge and attitudes regarding HPV infection and vaccination among a representative sample of preadolescents of Palermo, Italy. A survey was carried out throughout two questionnaires, before and after carrying out an educational intervention scheduled during school hours. A total of 1702 students attending first-grade secondary schools of the province of Palermo were enrolled (response rate 68.9%). Students attending third classes (adj OR = 1.18

MaleHealth Knowledge Attitudes PracticeHealth Toxicology and Mutagenesislcsh:MedicineUterine Cervical NeoplasmsAdult women0302 clinical medicineSurveys and Questionnaires030212 general & internal medicineChildPapillomaviridaeSicilyPapillomavirus VaccineResponse rate (survey)PracticeSchoolsSchool-based interventionHealth KnowledgeVaccinationPreadolescent studentHPV infectionSexually transmitted diseaseVaccinationEuropeKnowledgeHPV infection; HPV vaccine; attitude; knowledge; preadolescent students; school-based intervention; sexually transmitted diseases; vaccination; willingness; Child; Europe; Female; Humans; Male; Papillomavirus Infections; Papillomavirus Vaccines; Patient Acceptance of Health Care; Schools; Sicily; Surveys and Questionnaires; Uterine Cervical Neoplasms; Vaccination; Health Knowledge Attitudes Practice; PapillomaviridaeFemalewillingnesspreadolescent studentssexually transmitted diseaseseducationWillingneArticlePost-interventionLikert scale03 medical and health sciences030225 pediatricsmedicineHumansHuman papilloma virus infectionPapillomavirus VaccinesSocioeconomic statusPapillomavirus InfectionHPV vaccinebusiness.industrylcsh:RPapillomavirus InfectionsPublic Health Environmental and Occupational HealthPatient Acceptance of Health Caremedicine.diseaseAttitudeAttitudesHPV infectionbusinessDemography
researchProduct

Is there a lack of information on HPV vaccination given by health professionals to young women?

2013

Objective: The aim of this survey is to compare the main sources of information about vaccination against Human papillomavirus (HPV) of young women aged over-18 and under-18 years.Methods: A multicenter study was carried out in Italy through the administration of a questionnaire. Univariate analyses were conducted to evaluate possible differences between age groups and different locations (chi-square test and Fisher test where possible).Results: The sample consisted of 987 young women. The main sources of information about HPV vaccination are represented by magazines/books (23.1%) and TV (20.5%) for the over-18s, while for the under-18s the sources are general practitioners (22.6%) and pedi…

MaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyHPVAdolescentAlternative medicineUterine Cervical NeoplasmsHPV Source of information Vaccine Young womenNOYoung Adultsymbols.namesakeSurveys and QuestionnairesmedicineHumansPapillomavirus VaccinesChildSettore MED/42 - IGIENE GENERALE E APPLICATAFisher's exact testGynecologyCervical cancerUnivariate analysisGeneral VeterinaryGeneral Immunology and MicrobiologyHealth professionalsbusiness.industryPapillomavirus InfectionsVaccinationPublic Health Environmental and Occupational HealthHpv vaccinationProfessional-Patient Relationsmedicine.diseaseSource of informationTest (assessment)VaccinationInfectious DiseasesHealth CommunicationItalyFamily medicinesymbolsMolecular MedicineHPV; Source of information; Vaccine; Young womenFemaleYoung womenbusinessVaccine
researchProduct